Cardiac Amyloidosis Clinical Trials

The cardiac amyloidosis team at Cedars-Sinai is one of the few programs on the West Coast evaluating new treatments designed to reduce or stop heart damage caused by cardiac amyloidosis. You have the opportunity to take part in these efforts through clinical trials. We lead and participate in trials testing promising new drug therapies. These drugs may be the key to helping cardiac amyloidosis patients survive longer and with a better quality of life.

Condition

Transthyretin mediated amyloid cardiomyopathy

Participant Requirements:

  • 18-85 years old
  • Documented diagnosis of transthyretin amyloidosis with cardiomyopathy
  • Medical history of heart failure

Summary:

The purpose of this study is to evaluate the safety and investigational use of a drug called Patisiran and whether it may improve symptoms and quality of life in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy.

Condition

Transthyretin mediated amyloid cardiomyopathy

Participant Requirements:

  • 18-90 years old
  • Willing to be genetically tested for mutations in the TTR gene
    Transthyretin (TTR) amyloidosis
  • Not pregnant or lactating

Summary:

The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called ION-682884 in individuals who have transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a disease caused by change in a protein called transthyretin (TTR).

Have Questions or Need a Second Opinion?

To learn more or make an appointment, call or send a message to our cardiac amyloidosis experts. You also can have us call you back at your convenience.

Available 24 hours a day

(1-800-233-2771)